Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
Naloxone is a World Health Organization (WHO)-listed essential medicine and is the first choice for treating the respiratory depression of opioids, also by lay-people witnessing an opioid overdose. Naloxone acts by competitive displacement of opioid agonists at the μ-opioid receptor (MOR). Its effect depends on pharmacological characteristics of the opioid agonist, such as dissociation rate from the MOR receptor and constitution of the victim. Aim of treatment is a balancing act between restoration of respiration (not consciousness) and avoidance of withdrawal, achieved by titration to response after initial doses of 0.4–2 mg. Naloxone is rapidly eliminated [half-life ( t 1/2 ) 60–120 min] due to high clearance. Metabolites are inactive. Major routes for administration are intravenous, intramuscular, and intranasal, the latter primarily for take-home naloxone. Nasal bioavailability is about 50%. Nasal uptake [mean time to maximum concentration ( T max ) 15–30 min] is likely slower than intramuscular, as reversal of respiration lag behind intramuscular naloxone in overdose victims. The intraindividual, interindividual and between-study variability in pharmacokinetics in volunteers are large. Variability in the target population is unknown. The duration of action of 1 mg intravenous (IV) is 2 h, possibly longer by intramuscular and intranasal administration. Initial parenteral doses of 0.4–0.8 mg are usually sufficient to restore breathing after heroin overdose. Fentanyl overdoses likely require higher doses of naloxone. Controlled clinical trials are feasible in opioid overdose but are absent in cohorts with synthetic opioids. Modeling studies provide valuable insight in pharmacotherapy but cannot replace clinical trials. Laypeople should always have access to at least two dose kits for their interim intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Time course (left: 0–240 min, right: 0–60 min) of plasma concentrations of intravenous and intramuscular naloxone (0.4 mg) and concentrated intranasal formulations of 1, 2, and 4 mg naloxone. Note the initial closeness of serum concentrations of the regulatory golden standard 0.4 mg intramuscular dose and the 2 mg intranasal dose. Note also that plasma concentrations after 2 mg intranasal naloxone surpass that of 0.4 mg intramuscular naloxone after 6 min and stay above that of intramuscular for the remaining 120 min. Also, note the dramatic overshoot by the 4 mg dose compared with the 0.4 mg intramuscular dose. Redrawn from McDonald et al. [83] with permission](https://figures.cochat.ai/paper-figures/af98393d605c4f64b63e2642619cc2eb/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-2.jpg)
![Fig. 3 Dose–concentration linearity for maximum serum concentration (Tmax) and area under the curve (AUC) after nasal spraying of 0.8–2.0 mg of concentrated nasal naloxone formulations in healthy volunteers (compiled from two different studies [48, 62] with the same formulation). This linearity is the scientific basis for a two-dose administration by laypeople in take-home naloxone (THN)](https://figures.cochat.ai/paper-figures/8d8ad05c57804a1cb930ebc329e3741c/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-3.jpg)
![Fig. 4 Inter- and intraindividual variability of the absolute bioavailability of intranasal naloxone [AUC(IN)/AUC(IV) × DOSE(IV)/DOSE(IN)] based on AUC0−inf in 22 healthy volunteers. Not only does the absolute nasal bioavailability vary from about 20% to almost 100% between individuals but also is usually reproduced in an individual. Similar findings were observed for the relative intranasal to intramuscular bioavailability in the same subjects [19]](https://figures.cochat.ai/paper-figures/60c0086d84d04aa1a3816c462545ec6c/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-4.jpg)
![Fig. 5 Time course of pupil diameter in healthy volunteers exposed to remifentanil and naloxone [n = 12, mean (95% confidence interval)]. Remifentanil was started at t = −12 min and stopped at t = 90 min (orange, horizontal line). Miosis was rapidly reversed by a naloxone bolus of 1 mg intravenously given at t = 0. The blue broken line is the regression line [f(x) = − 0.0292x + 6.9924)] and is based on the period 19–89 min. It crosses the nadir baseline (black dotted line) at 118 min. The blood concentration of naloxone at this point was 0.5 ng/ml, which is the minimum effective concentration of naloxone in steady state. Redrawn from Tylleskar et al. [63] with permission](https://figures.cochat.ai/paper-figures/578f4a8864ce412a8c8ee73b51100f6f/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-5.jpg)
![Fig. 6 Hysteresis plot of pupil diameter and naloxone concentration during a remifentanil infusion with stable blood concentrations (see legend for Fig. 5). The red line represents arterial samples, and the blue line represent venous samples. The direction of time is illustrated by the arrow. This finding allows for the use of venous concentrations in PK/PD modeling. Redrawn from Tylleskar et al. [63] with permission](https://figures.cochat.ai/paper-figures/b220aa8ae742457b8a62ffa4a663d065/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-6.jpg)
![Fig. 7 Simulated time courses of mean naloxone concentrations (lines) and standard deviations as shaded areas: 0.8 mg intramuscular (dark gray), 0.4 mg intramuscular (light gray), and 1.4 mg intranasal (blue). Time of administration of injected naloxone is t = 0 min. A Intranasal 1.4 mg administered 10 min prior to injected naloxone (0.4 and 0.8 mg). B Simulation of the shortest time (2.25 min) beneficial to administer the intranasal spray, rather than wait for naloxone to be injected by medical personnel. C Simulation of 1.4 mg intranasal naloxone when intramuscular 0.4 mg naloxone is injected to a patient 10 min before the intranasal dose. Redrawn from Skulberg et al. [77]](https://figures.cochat.ai/paper-figures/e36c40238a254694b601924d47af563e/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-7.jpg)
![Fig. 8 Simulated concentration–time profiles of plasma naloxone after various common clinical dosing schemes in opioid overdose. A pharmacokinetic model based on our own data and 1000 simulations were used (Anesthesiology, manuscript in review) [108]. Two intravenous (0.4 and 2 mg, shown in gray and black, respectively) and three intramuscular doses (0.4, 0.8, and 2.0 mg, shown in light blue, yellow and blue, respectively) were simulated using the final pharmacokinetic model. The lower dotted line suggests the duration of action, represented by an experimentally determined minimum effective concentration of 0.5 ng/ml [76] and the upper dotted line suggests an increased risk of withdrawal, represented by the Cmax (3.2 ng/ml) and 0.8 mg intramuscular dose [18, 109]](https://figures.cochat.ai/paper-figures/85677e99c40a46719425a695c6f3385b/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-8.jpg)
![Fig. 9 Simulated plasma concentration profiles after single bolus doses (0.9, 1.4, 2.0, or 4.0 mg) of intranasal naloxone, alone or with remifentanil dosing (A and B, respectively) using a pharmacokinetic model based on our own data (Anesthesiology, manuscript in review) [108]. Plasma concentration–time course of the regulatory golden standard, an intramuscular 0.4 mg bolus dose, is shown in blue](https://figures.cochat.ai/paper-figures/c080496a8e7b45d281e0d6f2b31e4458/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-9.jpg)
![Fig. 10 A randomized, double-blinded comparison of naloxone given intramuscularly (0.8 mg, blue) or intranasally (1.4 mg, brown) by the ambulance service in opioid overdose (n = 201) Shaded areas represent 95% confidence interval. Kaplan–Meier plot showing the probability of not having reached satisfactory respiration (10 breaths/min). Curves are similar until 3 min, and the restoring of respiration is 2.3 min slower after the intranasal dose at 10 min. In real life, this difference is probably smaller, as intranasal administration is likely faster to complete than intramuscular. These intoxications were also more serious than those in an unselected material in the same catchment area [110]. Redrawn from Skulberg et al. [73]](https://figures.cochat.ai/paper-figures/dac41243484b4e5ab028ddedcda09040/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, interindividual tolerance to different opioids varies greatly from opioid-naive patients to patients who use opioids regularly.”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nitazene’s high potency and activation at the mu opioid receptor allows for naloxone reversal through competitive antagonism at this exact receptor [36].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early naloxone administration remains critical because reversal of opioid respiratory depression reduces the mortality risk of these drugs [36].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [36]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is highlighted for morphine, as its serum concentrations were significantly higher in patients receiving intravenous morphine for cancer-related pain than in all morphine-positive post-mortem cases in another study [14,47].”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [47]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S., & Kauffman, R. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035092 · Cited by 2,421
Mould, D., & Upton, R. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.14 · Cited by 897
Management of Opioid Analgesic Overdose
Boyer, E. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1202561 · Cited by 605
Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development
Mould, D., & Upton, R. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.4 · Cited by 544
EEG Quantitation of Narcotic Effect: The Comparative Pharmacodynamics of Fentanyl and Alfentanil
Scott, J. C., Ponganis, K. V., & Stanski, D. R. (1985) · Anesthesiology · doi:10.1097/00000542-198503000-00005 · Cited by 492
McDonald, R., & Strang, J. (2016) · Addiction · doi:10.1111/add.13326 · Cited by 471
Self-citationNaloxone dosage for opioid reversal: current evidence and clinical implications
Rzasa Lynn, R., & Galinkin, J. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617744161 · Cited by 346
Pharmacokinetics of Naloxone in Rats and in Man: Basis for Its Potency and Short Duration of Action
Ngai, S. H., Berkowitz, B. A., Yang, J. C., Hempstead, J., & Spector, S. (1976) · Anesthesiology · doi:10.1097/00000542-197605000-00008 · Cited by 287
Nasal administration of opioids for pain management in adults
Dale, O., Hjortkjær, R., & Kharasch, E. D. (2002) · Acta Anaesthesiologica Scandinavica · doi:10.1034/j.1399-6576.2002.460702.x · Cited by 270
Self-citation
Research works printed but not linked: 6
- Garfield E. The 1982 John Scott Award goes to Jack Fishman and Harold Blumberg for synthesis and investigations on naloxone. Essay Inf Sci. 1983;6:121–30.
- Blumberg H, Dayton HB, George M, Rapaport DN. N-allylnoroxynorphone; a potent narcotic antagonist. Fedn Proc Fedn Am Soc. 1961;20:311.
- Naloxone. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Naloxone#section=3D-Conformer. Accessed Oct 26 2022.
- World Health Organization, Management of Substance Abuse Team. Community management of opioid overdose. Geneva: World Health Organization; 2014.
- Lemen PM, Garrett DP, Thompson E, Aho M, Vasquez C, Park JN. High-dose naloxone formulations are not as essential as we thought. medRxiv. 2023;6:63.
- World Health Organization. WHO guidelines approved by the guidelines. Review committee community management of opioid overdose. Geneva: World Health Organization; 2014.
Cited by
Nitazenes: review of comparative pharmacology and antagonist action
Stangeland, M., Dale, O., & Skulberg, A. K. (2025) · Clinical Toxicology · doi:10.1080/15563650.2025.2504133 · Cited by 34
Self-citationA call for compassionate opioid overdose response
Russell, E., Hawk, M., Neale, J., Bennett, A. S., Davis, C., Hill, L. G., Winograd, R., Kestner, L., Lieberman, A., Bell, A., et al. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104587 · Cited by 28
Stevens, A., Keemink, J. R., Shirley‐Beavan, S., Khadjesari, Z., Artenie, A. A., Vickerman, P. T., Southwell, M., & Shorter, G. W. (2024) · Drug and Alcohol Review · doi:10.1111/dar.13908 · Cited by 27
Synthetic opioids have disrupted conventional wisdom for treating opioid overdose
Skolnick, P., Paavola, J., & Heidbreder, C. A. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100268 · Cited by 19
Naloxone dosing in the era of synthetic opioids: Applying the Goldilocks principle
Utrilla, M. G., Chesney, E., Neale, J., Metrebian, N., Kalk, N. J., Skulberg, A. K., Dietze, P., Smith, M. P., & Strang, J. (2025) · Addiction · doi:10.1111/add.70060 · Cited by 16
Self-citation
Metadata
- Authors
- Saari, T. I., Strang, J., & Dale, O.
- Affiliations
- University of Turku (FI)
- King's College London (GB)
- Norwegian University of Science and Technology (NO)
- Corresponding author
- Dale, Ola
- Venue
- Clinical Pharmacokinetics
- Published
- 2024-03-14
- Volume
- 63
- Issue
- 4
- Pages
- 397-422
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC11052794
- OpenAlex
- W4392796714
- Cited by
- 77
- References
- 154
- Citations by year
- 2026: 41 · 2025: 29 · 2024: 7
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UTUPub (University of Turku) (submittedVersion, cc-by-nc)
- Funders
- NTNU Norwegian University of Science and Technology
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- naloxone, opioid overdose, respiratory depression, mu-opioid receptor, pharmacokinetics, pharmacodynamics, intranasal administration, take-home naloxone, heroin overdose, fentanyl overdose, pharmacokinetic variability
- MeSH terms
- Administration, Intranasal, Analgesics, Opioid, Animals, Half-Life, Humans, Naloxone, Narcotic Antagonists, Drug Overdose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. https://app.cochat.ai/papers/10.1007/s40262-024-01355-6
- The paper
- Saari, T. I., Strang, J., & Dale, O. (2024). Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01355-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.